Ligand Pharmaceuticals Incorporated Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated asset resilience ratio. Ligand Pharmaceuticals Incorporated (LGND) has an Asset Resilience Ratio of 16.06% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Ligand Pharmaceuticals Incorporated for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ligand Pharmaceuticals Incorporated (1999–2025)
Asset resilience ratio of Ligand Pharmaceuticals Incorporated from 1999 to 2025. This chart shows how Ligand Pharmaceuticals Incorporated's Asset Resilience Ratio has changed over time. See Ligand Pharmaceuticals Incorporated free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Ligand Pharmaceuticals Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LGND current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $351.06 Million | 16.06% |
| Total Liquid Assets | $351.06 Million | 16.06% |
Asset Resilience Insights
- Good Liquidity Position: Ligand Pharmaceuticals Incorporated maintains a healthy 16.06% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Ligand Pharmaceuticals Incorporated Industry Peers by Asset Resilience Ratio
Compare Ligand Pharmaceuticals Incorporated's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Ligand Pharmaceuticals Incorporated Asset Resilience Ratio by Year (1999–2025)
Ligand Pharmaceuticals Incorporated asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Ligand Pharmaceuticals Incorporated.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.79% | $558.59 Million | $1.56 Billion | +16.27pp |
| 2024-12-31 | 19.52% | $183.86 Million | $941.77 Million | +0.80pp |
| 2023-12-31 | 18.72% | $147.35 Million | $787.22 Million | -3.16pp |
| 2022-12-31 | 21.88% | $166.86 Million | $762.67 Million | -2.90pp |
| 2021-12-31 | 24.78% | $321.59 Million | $1.30 Billion | -1.90pp |
| 2020-12-31 | 26.69% | $363.57 Million | $1.36 Billion | -40.09pp |
| 2019-12-31 | 66.78% | $998.32 Million | $1.49 Billion | +63.12pp |
| 2018-12-31 | 3.66% | $46.19 Million | $1.26 Billion | -23.32pp |
| 2017-12-31 | 26.98% | $181.04 Million | $671.02 Million | +6.65pp |
| 2016-12-31 | 20.33% | $122.30 Million | $601.59 Million | +1.08pp |
| 2015-12-31 | 19.25% | $102.79 Million | $533.93 Million | +16.49pp |
| 2014-12-31 | 2.76% | $7.13 Million | $258.03 Million | -1.38pp |
| 2013-12-31 | 4.14% | $4.34 Million | $104.71 Million | +1.49pp |
| 2012-12-31 | 2.65% | $2.77 Million | $104.26 Million | -5.52pp |
| 2011-12-31 | 8.17% | $10.00 Million | $122.35 Million | -17.44pp |
| 2010-12-31 | 25.61% | $19.35 Million | $75.56 Million | -7.11pp |
| 2009-12-31 | 32.72% | $37.20 Million | $113.70 Million | +2.44pp |
| 2008-12-31 | 30.28% | $51.92 Million | $171.45 Million | +20.13pp |
| 2007-12-31 | 10.15% | $17.60 Million | $173.28 Million | +6.03pp |
| 2006-12-31 | 4.12% | $13.45 Million | $326.05 Million | -2.29pp |
| 2005-12-31 | 6.41% | $20.17 Million | $314.62 Million | +0.34pp |
| 2004-12-31 | 6.07% | $20.18 Million | $332.47 Million | -7.21pp |
| 2003-12-31 | 13.28% | $40.00 Million | $301.25 Million | +5.21pp |
| 2002-12-31 | 8.07% | $21.82 Million | $270.61 Million | -6.36pp |
| 2001-12-31 | 14.43% | $16.95 Million | $117.47 Million | +1.70pp |
| 2000-12-31 | 12.73% | $14.44 Million | $113.42 Million | -0.12pp |
| 1999-12-31 | 12.85% | $17.30 Million | $134.60 Million | -- |
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help figh… Read more